GTCR’s $922 Million Acquisition of Albany Molecular Research

Credit Suisse Securities (USA) LLC is acting as exclusive financial advisor to AMRI and provided a fairness opinion to a special committee of the Board of Directors of AMRI. Goodwin Procter LLP is acting as legal advisor to AMRI in connection with the transaction. Latham & Watkins LLP is acting as legal advisor and Barclays and Morgan Stanley & Co. LLC are acting as financial advisors to Carlyle in connection with the transaction. Kirkland & Ellis LLP is acting as legal advisor and RBC Capital Markets LLC is acting as financial advisor to GTCR in connection with the transaction.

Albany Molecular Research, Inc. (NASDAQ: AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced it has signed a definitive agreement to be acquired by affiliates of The Carlyle Group (“Carlyle”) and GTCR LLC (“GTCR”) for $21.75 per share in cash.

This represents a 42% premium to the 60-day weighted average closing stock price leading up to April 5, 2017 (the last trading day prior to public rumors in the press regarding a potential sale process).

The agreement was unanimously approved by AMRI’s Board of Directors which has recommended that the shareholders vote in favor of the transaction.

Kirkland & Ellis LLP advised GTCR LLC with a team led by corporate partners Sanford Perl (Picture), Michael Weed, William Sorabella, Daniel Guerin and Christopher Butler.

The Goodwin team was led by partners Stuart Cable, Danielle Lauzon, James Matarese and included associates William Collins, Courtney Gaughan, Amoli Pandya, Richard Evans, and Brian Fleming.

Involved fees earner: Stuart Cable – Goodwin Procter; James Matarese – Goodwin Procter; Richard Evans – Goodwin Procter; Brian Fleming – Goodwin Procter; William Collins – Goodwin Procter; Danielle Lauzon – Goodwin Procter; Courtney Gaughan – Goodwin Procter; Amoli Pandya – Goodwin Procter; Sanford Perl – Kirkland & Ellis; Michael Weed – Kirkland & Ellis; William Sorabella – Kirkland & Ellis; Daniel Guerin – Kirkland & Ellis; Christopher Butler – Kirkland & Ellis;

Law Firms: Goodwin Procter; Kirkland & Ellis;

Clients: GTCR; Albany Molecular Research Inc.;


Author: Ambrogio Visconti